5-Amino-1MQ: The NNMT-Inhibitor Fat-Loss Evidence Reviewed (2026)

Last updated: June 2026

Medical disclaimer: This article is for informational purposes only and is not medical advice. 5-Amino-1MQ is not FDA-approved for any clinical use and the evidence is preclinical only. Do not start, stop, or change any treatment based on what you read here. Consult a licensed clinician.

5-Amino-1MQ shows up in peptide forums next to BPC-157 and tirzepatide. But it doesn't belong to the peptide family at all. It's a small molecule. A research chemical with a single clear job: block an enzyme called NNMT.

The marketing promise is fat loss without dieting. The actual data is a handful of mouse studies. This review lays out what those studies found, what they didn't, and where the honest line sits between the two.

What is 5-Amino-1MQ?

5-Amino-1MQ is a small-molecule research compound, not a peptide. Its full chemical name is 5-amino-1-methylquinolinium, and it works by inhibiting the enzyme nicotinamide N-methyltransferase (NNMT).

This matters for anyone reading peptide research. Peptides are short chains of amino acids. 5-Amino-1MQ is a single, ring-shaped quinolinium molecule. Different class, different chemistry, different rules.

The peptide-research crowd treats it as one of their own anyway. It gets sold by the same vendors. It targets the same goal most metabolic peptides chase: less body fat. So it ends up in the conversation.

The compound came out of medicinal chemistry work on NNMT inhibitors. Researchers wanted a membrane-permeable molecule that could shut down NNMT inside cells (Neelakantan et al., 2018, PMID 29155147). 5-Amino-1MQ was one of the lead compounds that came out of that effort.

How does NNMT inhibition affect fat cells and metabolism?

NNMT burns through two key cellular resources, SAM and NAD+, when it methylates vitamin B3. Blocking NNMT is meant to preserve those resources and push fat cells toward burning more energy.

Here's the chain. NNMT takes a methyl group from S-adenosylmethionine (SAM) and sticks it onto nicotinamide, a form of vitamin B3 (Pissios, 2017, PMID 28291578). That reaction does two things at once.

It eats up SAM, the cell's main methyl donor. And it pulls nicotinamide out of the pool the cell uses to make NAD+, a molecule tied to energy metabolism. NNMT sits at the crossroads of methyl-group supply and the methionine cycle (Eckert et al., 2019, PMID 30226369).

When NNMT runs hot, those resources drain. The theory: fat cells slow their energy expenditure and store more. NNMT is found at high levels in fat tissue and rises in obesity and diabetes (Pissios, 2017, PMID 28291578).

So if you block NNMT, the logic goes, SAM and NAD+ stay available. Fat cells ramp up energy expenditure instead of hoarding fat. That's the pitch. The next section covers whether mice actually showed it.

What does the preclinical evidence show?

In diet-induced obese mice, NNMT inhibition reduced body weight, white fat mass, and adipocyte size. The foundational finding came from a 2014 Nature study showing NNMT knockdown protects against obesity.

Start with the Nature paper. Kraus and colleagues knocked down NNMT in the fat tissue of mice fed a high-fat diet (Kraus et al., 2014, Nature 508:258-262, PMID 24717514). The mice were protected from obesity, glucose intolerance, and fatty liver.

The mechanism lined up with theory. Knocking down NNMT raised oxygen consumption and bumped up energy expenditure. Relative fat mass dropped by roughly 47% versus controls. That study put NNMT on the map as a metabolic target.

Then came the small molecule. Neelakantan and colleagues gave diet-induced obese mice an NNMT inhibitor — 5-Amino-1MQ is the compound most associated with this work — at about 20 mg/kg/day for 11 days (Neelakantan et al., 2018, PMID 29155147). Body weight fell. White adipose mass fell. Fat-cell size shrank.

Notably, food intake didn't change. The mice didn't eat less. Plasma total cholesterol also dropped in treated animals. That's the result the fat-loss marketing leans on.

A separate line of work looked at muscle, not fat. An NNMT inhibitor reactivated aged muscle stem cells and improved regeneration and strength after injury in mice (Neelakantan et al., 2019, PMID 30753815). That's where the "muscle and aging" claims come from.

More recent rodent work continued to support NNMT inhibition for obesity-related metabolic problems (2024, PMC11622326). Review articles now describe NNMT as a candidate target for metabolic syndrome (Li et al., 2024, PMC11196770). See the <a href="#study-table">study table</a> below for the full picture.

One thing to keep front of mind. Every result above is in mice. Mouse metabolism is not human metabolism. A compound that works in a rodent often fails in people.

Is there any human evidence for 5-Amino-1MQ?

No. There are no published human clinical trials for 5-Amino-1MQ as of mid-2026. Every efficacy claim rests on animal data.

Let's be blunt about this, because the supplement marketing is not. As of June 2026, there is no completed Phase 1, 2, or 3 trial published in the peer-reviewed literature, and no results-reported study on ClinicalTrials.gov for 5-Amino-1MQ.

There is no FDA-approved indication. There is no public Investigational New Drug record. The compound has not cleared the basic human-safety steps that any drug must pass before efficacy testing.

That gap is the whole story. "Reduced fat mass in obese mice over 11 days" and "helps people lose weight" are separated by years of trials that have not happened. Anyone selling 5-Amino-1MQ as a weight-loss product is selling ahead of the evidence.

If you want a sense of how rigorous human-grade evidence reshapes a compound's story, our research-compound coverage of retatrutide shows what a drug actually moving through human trials looks like by comparison.

What are the reported dosing forms?

5-Amino-1MQ is most often sold as an oral capsule, with vendors citing 50–150 mg daily ranges. This is observational reporting of what's on the market, not a dosing recommendation.

The mouse studies used injectable dosing by body weight. The consumer market went a different direction: oral capsules. That's worth flagging on its own — the route that worked in studies isn't the route being sold.

Vendors commonly list daily amounts somewhere between 50 and 150 mg. There is no validated human dose because there are no human trials to set one. Any number you see is a guess dressed up as a protocol.

We are not endorsing any dose. There is no established safe or effective human dose for this compound. Oral bioavailability, absorption, and how it behaves in the human body are not established in published research.

What are the risks and unknowns?

The biggest risk is the unknown. No human safety data exist, NNMT does more than control fat, and research-chemical purity is inconsistent.

NNMT is not a fat-only switch. It's involved in liver metabolism, cancer biology, and methyl-group balance across many tissues (Pissios, 2017, PMID 28291578). Blocking it long-term in humans could have effects nobody has measured.

Then there's the product itself. Research chemicals aren't held to pharmaceutical standards. Dose accuracy, purity, and contamination vary by vendor. Two bottles labeled the same can hold very different things.

Drug interactions are unstudied. Effects in people with liver or kidney issues are unstudied. Long-term use is unstudied. The honest summary: almost everything that matters for human safety is a blank.

For the broader picture on how unregulated research compounds compare to compounded medicines, see our guide on compounded peptides versus research chemicals.

Is 5-Amino-1MQ legal and FDA-approved in 2026?

5-Amino-1MQ is not FDA-approved for any use. It's sold under research-use-only labeling, which means it is not legal to market or sell for human consumption.

The "research use only" or "not for human consumption" label isn't decoration. It's the legal line vendors stand behind. The compound has no approval as a drug, supplement, or food.

Selling it for human use would put a vendor on the wrong side of FDA rules. That's why the labels read the way they do. It shifts the framing to laboratory research, where the legal footing is different.

For buyers, the practical takeaway is simple. You'd be purchasing an unapproved compound with no quality oversight and no legal standing as a therapy. Our peptide legality guide walks through how research-use-only status works across this whole category.

<a id="study-table"></a>

Study reference table

Study (author, year)	Model	Sample	Primary finding
Kraus et al., 2014 (Nature, PMID 24717514)	Diet-induced obese mice, fat-tissue NNMT knockdown	Mouse	NNMT knockdown protected against obesity; relative fat mass down ~47%; raised energy expenditure
Neelakantan et al., 2018 (Biochem Pharmacol, PMID 29155147)	Diet-induced obese mice, ~20 mg/kg/day for 11 days	Mouse	Reduced body weight, white fat mass, and adipocyte size; food intake unchanged; lower plasma cholesterol
Neelakantan et al., 2019 (Biochem Pharmacol, PMID 30753815)	Aged skeletal muscle, NNMT inhibitor	Mouse	Reactivated senescent muscle stem cells; improved regeneration and strength after injury
Pissios, 2017 (Trends Endocrinol Metab, PMID 28291578)	Review of NNMT biology	N/A (review)	NNMT depletes SAM and shifts NAD+ metabolism; elevated in obesity and diabetes
Eckert et al., 2019 (PMID 30226369)	Mechanistic study of methionine cycle	Cell / biochemical	NNMT interacts with methionine-cycle enzymes and regulates methyl-donor metabolism
Metabolic study, 2024 (PMC11622326)	Obese rodent model, NNMT inhibition	Mouse	NNMT inhibition mitigated obesity-related metabolic dysfunction
Li et al., 2024 (PMC11196770)	Review of NNMT in metabolic syndrome	N/A (review)	Frames NNMT as a candidate therapeutic target for metabolic syndrome

The bottom line

5-Amino-1MQ is a small-molecule NNMT inhibitor with a clean mechanism and a real signal in mice. Block the enzyme, spare SAM and NAD+, and obese mice lose fat without eating less. That part is genuinely interesting.

But the gap between mouse and human is the entire story. There are no published human trials. No FDA approval. No validated dose. The fat-loss claims you'll see in stores are running years ahead of the data that exists.

Treat it as what it is: a research compound at an early stage, sold under research-use-only labels. If you're weighing it, weigh it against options with more evidence behind them — and talk to a clinician first. For grounded alternatives, see our overview of what else works besides peptide therapy.

Related Reading

• Best Alternatives to Peptide Therapy: What Else Works (2026)
• Peptide Legality Guide (2026)
• Compounded Peptides vs. Research Chemicals (2026)
• Retatrutide Research Compound: What Is Known (2026)

Frequently asked questions

Is 5-Amino-1MQ a peptide? No. 5-Amino-1MQ is a small-molecule research compound — 5-amino-1-methylquinolinium — that inhibits the NNMT enzyme. Peptides are chains of amino acids, which this is not. It's grouped with peptides only because the same vendors and metabolic-research audience cover it.

Does 5-Amino-1MQ cause fat loss in humans? There is no human evidence that it does. The fat-loss findings come entirely from obese mice, where it cut body weight and fat mass over about 11 days. No published human trials exist as of June 2026, so any human fat-loss claim is unproven.

How does 5-Amino-1MQ work? It blocks nicotinamide N-methyltransferase (NNMT), an enzyme that consumes SAM and nicotinamide when it methylates vitamin B3. Inhibiting NNMT is meant to preserve SAM and NAD+ and push fat cells toward higher energy expenditure. This is supported in mice, not in people.

Is 5-Amino-1MQ FDA-approved or legal? It is not FDA-approved for any use and has no public IND record. It's sold under research-use-only labeling, meaning it is not legal to market or sell for human consumption. Buyers are purchasing an unapproved compound with no quality oversight.

What are the side effects of 5-Amino-1MQ? Human side effects are unknown because no human safety trials have been published. NNMT affects liver metabolism and methyl-group balance beyond fat tissue, so long-term inhibition carries unmeasured risks. Research-chemical purity also varies widely between vendors.

Researched and drafted by Theo Park, an AI editorial persona at Peptide Front, against published sources. Reviewed by our editorial team.